Blocknomi
Key Takeaways Shares of Regenxbio plummeted 25% to $8.05 following FDA’s clinical hold on gene therapy candidate RGX-121 An expanded imaging surveillance program detected asymptomatic nodules and cystic masses on…
Related articles
-
StarkWare Quantum Bitcoin Transaction: First Quantum-Resistant BTC Transaction Hits Mainnet
Cryptonews Published 27.08.2026 08:59
-
'The Government Doesn't Own Our Data': Prosecuted GrapheneOS User
Decrypt Published 26.08.2026 17:24
-
Strategy Slams Brakes on Bitcoin Buying, Stockpiles $6.69B Cash
Bitcoin.com Published 24.08.2026 12:30
-
CryptoQuant: Bitcoin’s Rally Was a Binance Short Squeeze, Not Spot Demand
BlockchainReporter Published 21.08.2026 14:30
-
XRP $1–$1.70 Range is the Foundation for Its Next Major Repricing
The Crypto Basic Published 28.08.2026 12:42
-
AI Data Center Backlash Is Being Politically Weaponized: Will Midterms Tip the Scales?
BeInCrypto Published 26.08.2026 22:40
-
Institutional Demand Is Back: Bitcoin and Ethereum ETF Inflows Reached 10-Month High
CryptoPotato Published 23.08.2026 11:02
-
Hyperliquid Group Asks CFTC To Approve Energy Perpetual Contracts
Blocknomi Published 27.08.2026 09:15